AI-Enabled Generative Design of Immune Cells and Receptors for Programmable Immunity

3.1. Technical Adaptation of Generative Architectures for Immunology

Although transformer and diffusion architectures originate from general-purpose machine learning, their application to immunology requires domain-specific adaptation of inputs, conditioning strategies, and physical constraints. In immune receptor design, the biological meaning of sequence context, evolutionary history, and structural feasibility must be explicitly encoded rather than treated as abstract tokens.

Multiple sequence alignments (MSAs) are processed in protein language models by representing aligned residues across homologous sequences as parallel input channels rather than linear sequences. In models such as the MSA Transformer, each alignment column is embedded jointly across sequences, allowing attention mechanisms to learn evolutionary covariation between residues [5,51]. For immune receptors, however, MSAs are often sparse or biased, particularly for TCRs, where extreme diversity and limited structural sampling reduce alignment depth. As a result, immune-focused adaptations either restrict MSA usage to framework regions, augment alignments with synthetic or inferred homologs, or replace MSAs with large-scale repertoire embeddings learned directly from unaligned sequences. In this context, models such as ESM-2 rely primarily on self-attention over raw sequences [44], allowing them to infer contextual constraints without requiring dense evolutionary alignments.

Physical constraints are incorporated through both architectural design and post-generation filtering. Structure-aware models such as ProteinMPNN and RFdiffusion represent proteins as graphs or geometric point clouds, where residues serve as nodes and spatial relationships define edges [6, 52-53]. These models learn conditional probability distributions over amino-acid identities or atomic coordinates given a fixed backbone, interface, or motif. In diffusion models, generation proceeds through iterative denoising steps that progressively enforce geometric consistency, steric feasibility, and backbone continuity. Training on experimentally determined structures enables these models to internalize folding rules, hydrogen bonding patterns, and packing constraints implicitly through loss functions that penalize geometric deviations.

In immune applications, these physical constraints are further refined through conditioning on antigenic context. For TCR design, structural templates of TCR–pMHC complexes define spatial constraints on complementarity-determining regions, particularly the CDR3 loop, which exhibits high flexibility [54,55]. Diffusion-based and structure-conditioned models address this extreme flexibility by decoupling rigid and flexible regions during generation. Framework regions are typically fixed or tightly constrained using backbone templates derived from known TCR structures, preserving global fold stability. In contrast, the CDR3 loop is either partially masked or assigned higher stochastic freedom during diffusion, allowing its backbone and side-chain geometry to be resampled more extensively. Conditional variables such as interface residue masks or antigen-contact maps restrict this flexibility to antigen-facing regions, ensuring that variability is focused on functional interface residues rather than destabilizing the overall receptor. This region-specific flexibility enables diffusion models to explore diverse CDR3 conformations while preserving the structural integrity of the conserved T cell receptor scaffold. Conditioning variables may include peptide–HLA embeddings, interface residue masks, or physicochemical features that bias generation toward shapes compatible with specific epitopes.

In addition to architecture-level constraints, most pipelines integrate physics-based post-processing. Generated sequences or structures are filtered using molecular-dynamics relaxation, energy minimization, or docking simulations to eliminate candidates that violate thermodynamic stability or steric feasibility [56,57]. This hybrid approach ensures that statistical plausibility learned by neural networks is grounded in physical reality, thereby reducing the risk of generating biologically implausible designs that are mathematically consistent but not physically viable.

To clarify how these architectures differ in data requirements, modeling strategies, accessibility, and immune engineering use cases, a comparative overview of major generative frameworks used in immunoengineering is provided in Supplementary Table S1.

While multiple generative architectures are now used in immunoengineering, they differ fundamentally in the types of biological information on which they operate. Protein language models such as ESM-2 primarily learn from sequence statistics and are well suited for exploring diversity in T cell receptor or antibody repertoires, whereas structure-aware models such as ProteinMPNN and RFdiffusion incorporate geometric constraints and are better suited for interface design and de novo binder generation. TCR-focused frameworks such as PhysicoGPTCR and ProteinMPNN-TCR represent emerging efforts to adapt these general-purpose architectures to immune-specific constraints, particularly antigen context and complementarity-determining region variability. In contrast, CAR-T design has largely relied on generative or reinforcement-learning frameworks trained on modular construct libraries, reflecting the engineering rather than evolutionary nature of CAR architectures.

3.2. Code Availability and Reproducibility

Given the rapid evolution of generative immunoengineering, transparency and code accessibility are essential to ensure reproducibility and enable independent benchmarking. The generative frameworks discussed in this review span open-source tools, research prototypes, and proprietary or study-specific systems.

Several widely used foundation models are openly available. ESM-2 and related protein language models are released by Meta AI with open-source code and pretrained weights [44]. ProteinMPNN, RFdiffusion, Chroma, and MSA Transformer are also distributed as open-source research tools with publicly accessible repositories, enabling independent replication and extension of published results [6, 53, 58].

In contrast, several immune-specialized frameworks, such as PhysicoGPTCR and ProteinMPNN-TCR, represent research prototypes whose code availability varies across studies [59]. Some implementations are partially released or shared upon request, while others remain internal to the originating research groups. Where code is not publicly available, such frameworks are explicitly designated as research prototypes rather than community tools. Generative CAR-design frameworks are frequently developed within academic–industrial collaborations or commercial platforms and are often proprietary or study-specific [60,61]. In such cases, methodological details are provided in publications, whereas source code and trained models are not made publicly available. Each framework discussed is explicitly labeled as open-source, partially open, or proprietary (Supplementary Table S1), and GitHub links are provided for tools with public repositories. Frameworks that are conceptual, hypothetical, or not accompanied by released code are clearly identified as such to avoid overstating their reproducibility.

Recent innovations have begun to integrate multimodal generative architectures that combine sequence, structure, and system-level data into unified frameworks. Variational autoencoders and diffusion models trained on multi-omic datasets can embed gene expression, protein abundance, and signaling dynamics within shared latent spaces [62,63]. These models enable not only receptor-level design but also the generation of synthetic cellular states, allowing prediction of how genetic or metabolic perturbations may influence functional phenotypes. When aligned with single-cell RNA sequencing, proteomic profiling, and CRISPR perturbation data, multimodal models allow researchers to simulate the outcomes of cellular reprogramming before executing experimental interventions [64]. This integration forms the conceptual foundation of generative immunoengineering, in which molecular design and cellular state control converge through shared representational learning.

Another essential component of this foundation is conditional generation, which introduces explicit control variables into the generative process. Conditioning can be achieved through structural templates, physicochemical features, antigenic context, or phenotype-level objectives [65]. In receptor engineering, conditional models can generate sequences that maximize predicted binding affinity to a specified epitope while minimizing cross-reactivity and immunogenicity [66,67]. In cell engineering, conditioning may involve the specification of transcriptional or metabolic profiles corresponding to desired states such as resistance to exhaustion, enhanced memory formation, or altered cytokine secretion [68,69]. By encoding these objectives into the generative process, the models move beyond unconstrained generation toward constrained biological design aligned with therapeutic objectives.

The reliability of generative models critically depends on the quality, diversity, and annotation of the training data. Immune-repertoire datasets such as IEDB, VDJdb, OAS, and PIRD provide millions of receptor sequences, yet these datasets are biased toward particular species, disease contexts, and sequencing platforms [70]. Structural datasets remain comparatively sparse, limiting model generalization for certain receptor classes or antigen types. Integrating curated experimental datasets with synthetic augmentation strategies, including contrastive learning and adversarial perturbation, has emerged as a strategy to expand functional diversity while maintaining biological plausibility [71]. Standardization of data formats and metadata annotations is equally important for ensuring reproducibility across laboratories and for enabling transparent benchmarking of model performance [72].

The theoretical strength of these models is complemented by their capacity for interpretability and embedding analysis, enabling mechanistic insight into learned representations. Techniques such as attention visualization, feature attribution, and latent-space interpolation have shown that protein language models implicitly capture biochemical hierarchies that resemble evolutionary phylogenies [43,73]. In immune systems, these embeddings encode information about complementarity-determining region composition, binding topology, and germline lineage relationships [74]. Understanding how models internalize these features not only enhances trust in generative predictions but also provides a new lens through which to examine the informational logic of the immune repertoire.

Together, these methodological pillars define the computational grammar of generative biology. The convergence of language-based, structure-aware, and multimodal approaches provides the mathematical substrate on which immune receptor and cell-state generation can occur with controllable precision. As models become larger and more contextually integrated, they begin to approximate a universal generator of biomolecular function, one capable of producing sequences, folds, and regulatory motifs that are both novel and biologically viable. In the context of immunoengineering, this synthesis enables the design of receptors, signaling networks, and phenotypic programs guided not solely by human intuition but by statistical representations of evolution and function embedded within artificial intelligence [75,76].

The next section will examine how these generative foundations are being applied to the design of immune repertoires and antigen-specific recognition, focusing on model architectures, conditioning strategies, and validation frameworks that connect digital generation to experimental reality.

4.1. Data Scarcity and Strategies for Learning Under Limited Structural Supervision

A fundamental bottleneck in TCR-specific generative design is the scarcity of high-quality paired TCR–pMHC structural data [59,89]. Compared with general protein databases, experimentally resolved immune complexes represent only a small and biased subset of possible receptor–antigen interactions. This limitation constrains direct supervised training of structure-aware generative models and necessitates strategies that learn under weak or indirect supervision.

One widely used strategy is transfer learning from large-scale protein corpora outside the immune system. Foundation models such as ESM-2, ProteinMPNN, and RFdiffusion are first trained on millions of generic protein sequences or structures, allowing them to internalize universal rules of folding, packing, and interface geometry [6, 44, 53, 90]. Immune-specific tasks are then addressed through fine-tuning or conditioning on relatively small TCR–pMHC datasets, effectively leveraging general protein knowledge to mitigate the sparsity of immune-specific data.

A second strategy involves using large-scale immune-repertoire sequencing as a proxy for structural supervision [4,91]. Although most repertoire datasets lack paired antigen or structural information, they capture statistical regularities in CDR usage, V(D)J recombination, and junctional diversity. Generative models trained on these repertoires learn the grammatical constraints of immune receptors, which can then be coupled to structural or antigen-conditioned models through multimodal or hierarchical architectures.

Synthetic data augmentation provides an additional route to overcoming small-data limitations. Structure prediction tools, docking algorithms, and molecular-dynamics simulations are used to generate approximate TCR–pMHC complexes from known sequences, expanding training sets beyond experimentally resolved structures [92,93]. Although these synthetic structures carry uncertainty, they enable models to explore broader interface geometries and can be filtered using energy-based or stability criteria.

Active learning and closed-loop design–build–test–learn (DBTL) frameworks further help mitigate data scarcity [94,95]. Generative models propose receptor candidates whose experimental testing is expected to yield maximal information gain. High-throughput binding assays, display systems, and single-cell functional screens then generate new labeled data, which are fed back into model retraining. This iterative strategy enables models to progressively improve even when initial labeled datasets are limited.

Finally, weakly supervised and contrastive learning approaches enable models to learn from partially labeled data, such as receptors known to bind a class of antigens without precise structural resolution [96,97]. By learning relative similarities rather than absolute labels, these methods extract useful signal from noisy or incomplete datasets and reduce dependence on fully resolved structures.

Learning immune specificity also depends on understanding contextual conditioning, in which receptor generation is guided by features of the antigen or by the cellular environment in which binding occurs. Conditional generative frameworks incorporate peptide–HLA embeddings, physicochemical descriptors, and even transcriptomic signatures of the responding cell population [98]. This conditioning enables models to generate receptors tailored to specific epitopes or immunological niches, rather than relying solely on global repertoire statistics. The resulting designs can be filtered by computational docking, binding-energy prediction, or molecular-dynamics relaxation to ensure structural plausibility and to screen for potential off-target interactions [99,100].

An equally important development is the use of contrastive and active learning strategies that couple model training with experimental feedback. High-throughput binding assays, yeast or mammalian display systems, and single-cell sequencing technologies provide empirical data that refine model priors through iterative updates [101-103]. Active learning enables the model to identify regions of uncertainty and to propose new receptor sequences whose experimental testing would maximize information gain. This closed-loop process progressively improves model fidelity and establishes an adaptive design framework that mirrors the iterative nature of immune evolution.

Despite these advances, challenges remain in ensuring that learned representations reflect biological causality rather than statistical correlation. Sequence redundancy, sampling bias, and limited negative examples can inflate apparent model accuracy while masking gaps in functional understanding [104]. The field is responding by developing standardized benchmarking platforms, curated cross-reactivity datasets, and transparent reporting frameworks for validation metrics that assess generalization across antigen classes and experimental systems [105,106]. Incorporating structural energetics, thermodynamic parameters, and molecular-simulation outputs into the training regime further grounds model predictions in biophysical reality [107,108].

Together, these developments illustrate a convergence between data-driven learning and structural immunology. By jointly modeling sequence, structure, and antigenic context, generative and representation models are beginning to reconstruct the underlying rules that govern immune recognition. In practical terms, they offer the capacity to generate receptor repertoires that are both diverse and functionally directed, to predict the cross-reactivity landscape of candidate therapeutics, and to guide the rational expansion of immune libraries toward desired antigen spaces. The integration of repertoire-scale learning with structural modeling thus constitutes the methodological core of generative immunoengineering, providing an analytical framework through which specificity can be understood, predicted, and engineered (Supplementary Table S2).

5.1. Designing Antigen-Specific Receptors

The adaptive immune system recognizes antigens through an immense repertoire of receptor sequences that encode highly specific binding topologies. Generative models trained on large-scale T-cell receptor (TCR) and antibody repertoires can recapitulate and extend this natural diversity. Transformer-based language models, such as PhysicoGPTCR, a physics-informed generative framework for T-cell receptor (TCR) design, employ contextual embeddings that capture residue-level physicochemical properties while conditioning sequence generation on peptide–HLA complexes or epitope descriptors [12, 111-112]. By sampling from latent spaces that integrate both sequence statistics and antigenic context, these models generate plausible receptor candidates that occupy unobserved yet biologically coherent regions of sequence space. A schematic overview of the PhysicoGPTCR architecture, including its conditioning, generation, and filtering stages, is shown in Figure 2.

In practice, these objectives are rarely independent and often compete. For example, increasing receptor affinity can compromise structural stability, broaden cross-reactivity, or elevate immunogenicity. Generative design therefore operates as a multi-objective optimization problem rather than a search for a single optimal solution. Reinforcement-learning based and active-learning frameworks address this challenge by optimizing multiple reward components simultaneously, identifying Pareto-optimal fronts that represent families of non-dominated receptor designs balancing competing objectives. Instead of reducing design to a single scalar score, these models preserve trade-offs among affinity, specificity, stability, and safety, enabling human designers to select candidates that best align with specific therapeutic priorities. In this sense, human-defined reward functions and constraints explicitly shape the evolutionary trajectory of AI-designed receptors, guiding exploration toward clinically acceptable regions of design space rather than maximal affinity alone [113-117].

5.2. Modular Optimization of Chimeric Antigen Receptors

Chimeric antigen receptors (CARs) are synthetic constructs that rewire immune recognition into an engineered signaling cascade. Each CAR consists of distinct functional modules: an extracellular binding domain, a hinge and transmembrane region, and one or more intracellular signaling motifs. The performance of a CAR depends on the integrated behavior of these modules, yet empirical optimization through domain swapping and screening is slow and labor-intensive [148]. Generative AI has introduced data-driven strategies capable of exploring this modular design space systematically [117].

Transformer-based models represent CAR components as compositional sequences encoding domain identity, positional order, and contextual interdependencies. By training on curated libraries of CAR constructs linked to phenotypic readouts, these architectures learn how variations in domain composition and arrangement modulate activation thresholds, cytokine signatures, and cellular persistence [149,150]. Conditional generation allows the creation of new CAR configurations optimized for desired functional signatures, such as reduced tonic signaling or enhanced metabolic fitness [151,152].

Reinforcement learning and active-learning algorithms further refine this design process. In these frameworks, model predictions are iteratively updated using experimental feedback from high-throughput CAR screening platforms, enabling convergence toward optimal constructs [153-155]. Such feedback loops have already produced CARs with modified hinge lengths and co-stimulatory domain combinations that yield improved cytotoxic performance and diminished exhaustion markers, demonstrating how iterative design–build–test–learn cycles can directly optimize CAR function through adaptive computational–experimental feedback [156].

Generative modeling also supports the design of armored CARs, which incorporate additional payload modules such as cytokine secretion cassettes, chemokine receptors, or immune checkpoint inhibitors. By embedding these additional modules within the same representational space, AI models can co-optimize receptor binding and paracrine modulation, resulting in constructs tailored for hostile tumor microenvironments [157,158]. Collectively, these developments illustrate how generative frameworks transform CAR engineering from heuristic assembly into a rational optimization problem that can be addressed using machine learning.

5.3. Engineering Logic-Gated and Multiplexed Architectures

A further evolution of receptor design involves encoding logical operations into immune constructs. Logic-gated CARs and TCRs employ multi-antigen recognition to refine specificity and reduce off-target cytotoxicity [159]. Generative modeling enables systematic exploration of these multi-input architectures by representing antigens, linkers, and signaling modules within a shared latent space. In solid tumors, generative models are being used to design multispecific and logic-gated CAR architectures that enhance selectivity and persistence while reducing off-tumor toxicity [160]. Conditional diffusion or variational models can generate dual-specific binding domains whose cooperative interactions produce Boolean outcomes such as AND, OR, or NOT responses depending on antigen co-expression patterns [161].

These models enable computational optimization of interdomain spacing, linker composition, and binding affinity ratios required for balanced activation. By simulating dose–response landscapes across predicted antigen concentrations, AI systems can identify configurations that achieve strong tumor selectivity while sparing healthy tissues [2,162]. In addition, machine-learning-guided sampling of co-stimulatory domain combinations enables fine-tuning of intracellular signaling strength and timing [163,164]. Such multi-objective optimization integrates molecular recognition with system-level control, extending the reach of generative immunoengineering beyond molecular design to programmable cellular logic.

Multiplexed receptor architectures, which incorporate multiple signaling channels within a single cell, also benefit from generative approaches. Models trained on combinatorial libraries of bispecific or tandem CARs learn statistical relationships between module composition and functional synergy [165,166]. The ability to generate thousands of candidate architectures in silico and evaluate them using predictive scoring significantly accelerates discovery, particularly for solid tumor targets that require simultaneous recognition of multiple antigens.

5.4. Integrating Computational Design with Experimental Validation

The practical utility of generative receptor design depends on its integration with empirical validation. High-throughput display technologies, including yeast, phage, and mammalian systems, provide experimental evidence that grounds model predictions [167]. Single-cell transcriptomic and proteomic profiling captures downstream functional outcomes and provides data for retraining generative models through active learning [168,169].

These advances have given rise to adaptive design–build–test–learn (DBTL) frameworks, in which computational generation and laboratory experimentation are linked through iterative feedback loops. Within such closed-loop systems, generative models propose receptor or construct candidates, automated biofoundries synthesize and screen them, and the resulting empirical data are reintegrated to update model priors. This adaptive coupling between in silico inference and in vitro validation constitutes the operational core of generative immunoengineering.

Closed-loop pipelines are emerging in which model-generated receptor or construct libraries are automatically synthesized, expressed, and screened. The resulting activity and expression data are fed back into the model to update its priors, progressively improving generative accuracy [170]. These DBTL-driven feedback cycles enable continuous hypothesis generation, experimental execution, and model refinement to occur as a coordinated, self-correcting process under human oversight. This iterative design–build–test–learn cycle parallels the self-optimization processes characteristic of control theory and enables rapid convergence toward functional solutions.

Molecular dynamics simulations and energy-based filtering further ensure that generated sequences satisfy physical constraints [171]. Structural relaxation, solvent accessibility analysis, and free-energy estimation help eliminate unstable or non-functional designs before synthesis [172]. When combined with automated DNA assembly and cell-based assays, these computational safeguards reduce experimental cost and improve hit rates. Collectively, these elements establish a hybrid experimental-computational ecosystem in which the design-build-test-learn cycle functions as the organizing principle linking algorithmic design to biological realization.

6.1. Modeling the Cellular State Space

Immune cells occupy a high-dimensional state space defined by transcriptional, epigenetic, and metabolic variables that dynamically evolve in response to environmental stimuli. Traditional analytical frameworks, such as clustering or trajectory inference, describe these states retrospectively but do not predict how they can be reprogrammed [184,185]. Generative models, including variational autoencoders (VAEs), diffusion probabilistic models, and generative adversarial networks (GANs), provide a fundamentally different capability: they learn the underlying probability distribution of cellular states and can interpolate within, or sample from, this learned manifold to predict previously unseen or engineered phenotypes [186,187].

While these models are powerful in learning associations between gene expression patterns and phenotypic states, association alone is insufficient for true cellular programming. A transcriptional profile that resembles memory, persistence, or exhaustion does not imply that inducing that profile will cause a stable phenotypic transition. Programming immune cells ultimately requires intervention in causal regulatory networks, rather than merely reproducing correlational signatures. The central challenge, therefore, lies in moving from descriptive statements of the form “this gene-expression state resembles memory” to actionable causal hypotheses such as “perturbing these regulators will induce and stabilize a memory phenotype.” This shift reframes generative phenotype modeling from a retrospective pattern-matching exercise into a forward-looking control problem centered on causal intervention.

A key limitation of current generative phenotype models is that most are trained primarily on observational single-cell datasets rather than on systematic perturbation experiments. As a result, their ability to predict the outcomes of radical or out-of-distribution reprogramming remains largely unvalidated. Models may interpolate reliably within the manifold of observed states but fail when asked to extrapolate to phenotypes that require coordinated, multi-node regulatory intervention. Addressing this limitation will require deeper integration of Perturb-seq data, causal inference frameworks, and closed-loop experimental validation to ensure that predicted interventions yield the intended phenotypic outcomes in living cells.

When trained on large-scale single-cell RNA sequencing (scRNA-seq) or ATAC-seq datasets, VAEs capture latent variables that correspond to biological processes such as activation, exhaustion, or memory differentiation [188-190]. These latent representations can be manipulated to simulate trajectories of transcriptional reprogramming. For instance, altering specific latent dimensions can emulate transitions from naïve to effector or from effector to exhausted states, revealing regulatory dependencies that govern these transitions. The learned latent manifold effectively approximates the probabilistic topology of the immune cell state landscape, providing a computational analogue to Waddington’s epigenetic landscape that is learned directly from data. Diffusion-based frameworks extend this capacity by modeling the stochastic evolution of gene-expression profiles, providing a generative account of cell-state dynamics over pseudo-temporal trajectories [191,192].

In parallel, multimodal models that integrate transcriptomic, proteomic, and metabolomic features are beginning to capture the coupled regulation of gene expression and metabolism in activated immune cells. Such models enable the generation of hypothetical phenotypes characterized by defined metabolic adaptations, cytokine secretion profiles, or migratory capacities [193,194]. By conditioning on environmental variables such as hypoxia, nutrient availability, or cytokine gradients, these frameworks can simulate how immune cells would adapt under diverse microenvironmental conditions [195]. However, the accuracy of such simulations remains constrained by the completeness and batch-corrected quality of training data, emphasizing the ongoing need for harmonized multimodal datasets.

Crucially, this conditioning-based generative strategy reflects a deeper shift in underlying assumptions. Rather than treating immune phenotypes as discrete, historically observed states, generative frameworks assume that immune behavior occupies a continuous functional landscape that can be explored and extrapolated beyond naturally sampled examples. This perspective enables the algorithmic exploration of rare, transient, or experimentally inaccessible immune states and reinforces the generative paradigm as one of design rather than discovery alone.

6.2. Generative Reprogramming and Perturbation Modeling

The transition of generative modeling from descriptive to prescriptive use involves linking latent dimensions to actionable molecular interventions. Perturbation-based training strategies, such as those used in models like scGen and CPA (Compositional Perturbation Autoencoder), learn mappings between control and perturbed cellular states across thousands of experimental manipulations [196,197]. These models can then generate counterfactual predictions of how a given perturbation—such as gene knockout, cytokine exposure, or small-molecule treatment—would reprogram cellular transcriptional and proteomic profiles.

When coupled with CRISPR Perturb-seq data, generative models can prioritize candidate sets of transcriptional regulators predicted to bias cellular trajectories toward desired phenotypic outcomes, subject to experimental validation. This framework has been applied to predict reprogramming strategies that induce T-cell memory phenotypes or reverse exhaustion-associated transcriptional signatures [198-200]. In macrophages and dendritic cells, similar models have been used to explore how combinations of signaling inputs reshape inflammatory versus tolerogenic polarization states. These predictions can then guide targeted interventions using synthetic circuits, small molecules, or genome editing [201]. It is important to note that predictive fidelity depends on the coverage of the training manifold; models extrapolate reliably only within data-supported regions of perturbational space.

Integrating these models with reinforcement learning further enables iterative optimization of intervention strategies. The algorithm explores a combinatorial action space of perturbations and uses feedback from simulated outcomes to propose the most effective intervention sequences. This approach reframes cellular reprogramming as an optimization problem, in which artificial intelligence can assist in identifying promising sequences of interventions, enabling dynamic control of gene regulatory networks rather than static modification of individual targets.

6.3. Linking Generative Models to Synthetic Circuits

Generative modeling also provides a computational substrate for the design of synthetic gene circuits capable of driving desired cell state transitions [202,203]. Once a target phenotype, such as resistance to exhaustion, enhanced persistence, or altered cytokine balance, is defined in latent space, AI models can identify candidate regulatory motifs or signaling pathways that may need to be modulated to achieve that state. In this context, regulatory motifs may refer to either cis-regulatory DNA elements controlling transcriptional logic or dynamic feedback structures within signaling networks, depending on the level of abstraction. Synthetic biologists can then construct corresponding genetic circuits to implement these predicted control strategies.

For example, reinforcement learning coupled with gene-network simulations has been used to design circuit architectures that stabilize T-cell metabolic fitness by dynamically regulating glycolytic and oxidative pathways [204,205]. Diffusion-based generators trained on transcriptional responses to immune checkpoints have proposed feedback modules that mitigate activation-induced exhaustion [34,206]. Such designs translate the statistical regularities learned by generative models into actionable biological logic, closing the gap between abstract representation and physical implementation.

The integration of generative models with experimental libraries of promoters and enhancer elements further enables data-driven optimization of regulatory sequences. By learning the mapping between sequence composition and expression amplitude or inducibility, generative models can design synthetic regulatory elements that enable precise transcriptional tuning in engineered immune cells [207]. This capability is especially valuable for balancing effector potency and safety in next-generation CAR-T or TCR-engineered therapies, where overactivation or premature exhaustion can compromise efficacy.

6.4. Toward Closed-Loop Phenotype Design

A defining feature of generative phenotype modeling is the potential for closed-loop optimization in which computational predictions are continuously refined through empirical feedback [208]. Integration with high-throughput perturbation platforms, time-lapse imaging, and multi-omic profiling enables real-time assessment of how engineered interventions reshape cellular states [209]. Data from each iteration are used to update generative priors, improving accuracy and adaptability.

This closed-loop paradigm parallels the design–build–test–learn cycles established in molecular engineering, but operates at the systems level of cellular behavior [210,211]. Extending the molecular DBTL (design–build–test–learn) framework to the cellular systems level enables iterative refinement of both molecular components and emergent phenotypes within a unified feedback architecture. In these frameworks, the model acts as a control algorithm that continuously adjusts interventions to maintain desired phenotypic states, requiring standardized data formats and interoperable protocols to ensure reproducibility and safe automation. These systems could ultimately form the basis of autonomous, adaptive immunoengineering platforms in which AI proposes genetic or pharmacological modifications, laboratory systems execute them through automated microfluidic experimentation, and the resulting data are used to continuously retrain and refine the model in real time.

Implementing such feedback architecture requires not only computational sophistication but also standardized experimental protocols and interoperable data formats. Advances in laboratory automation, robotic culture systems, and real-time single-cell monitoring are making these integrations increasingly feasible. As models become capable of predicting the dynamic responses of engineered immune cells, phenotype programming may evolve from a trial-and-error discipline into a continuous adaptive optimization process [212].

The use of generative models to program immune cell phenotypes represents a conceptual expansion of synthetic immunology. It extends the logic of receptor and construct design into the realm of dynamic cellular behavior. By learning from the multidimensional data that describe activation, differentiation, and adaptation, AI systems can propose intervention strategies that achieve desired phenotypic equilibria with minimal experimental iteration [213]. The resulting convergence of generative modeling, perturbation analysis, and synthetic circuit design transforms cellular reprogramming from a descriptive science into a predictive and creative enterprise.

In this emerging framework, immune cells may increasingly be treated as programmable entities whose behavior can be guided through data-informed and experimentally validated intervention strategies. This capacity to generate and stabilize beneficial phenotypes, whether through transcriptional modulation, metabolic rewiring, or synthetic gene networks, constitutes a central milestone on the path toward programmable immunity (Figure 3).

7.1. The Design Phase: Generative Hypothesis Formation

In the generative paradigm, design constitutes a computational experiment in which the model explores the probability distribution of biological functions. Large foundation models trained on multi-omic and structural datasets generate receptor sequences, circuit architectures, or cell-state perturbations that satisfy defined objective functions, including affinity, stability, specificity, metabolic resilience, and manufacturability [215,216].

Multi-objective reinforcement learning (MORL) and Pareto-front optimization are increasingly employed to balance these criteria, ensuring that improvements in one property do not come at the expense of others. For example, reinforcement agents can adjust generative sampling to favor constructs that maintain predicted folding stability while maximizing target binding and minimizing immunogenic epitopes [113-114, 147]. Bayesian optimization frameworks quantify uncertainty across latent dimensions and guide exploration toward regions of the design space where model confidence is low but potential reward is high.

At the cellular level, generative models design intervention strategies that reprogram gene-regulatory networks or metabolic fluxes to achieve stable phenotypes. These designs may take the form of predicted transcription-factor combinations, circuit topologies, or epigenetic modifications [116,217]. In silico simulations using agent-based or ODE-based digital twins of immune cells allow evaluation of predicted designs before synthesis, effectively providing pre-experimental validation within the design phase itself [115]. This digital pre-screening step serves as an internal “virtual test phase,” reducing wet-lab burden while improving safety and design traceability within the DBTL framework.

7.2. The Build Phase: Automated Synthesis and Cellular Integration

The build phase converts digital designs into tangible biological constructs. Modern biofoundries employ modular, high-throughput synthesis pipelines that integrate robotic liquid handling, automated cloning, and barcoded sample tracking systems. DNA assembly methods such as Golden Gate, Gibson, and enzymatic ligation-independent cloning enable parallel production of thousands of constructs in standardized vectors [218,219].

In immunoengineering, the build step involves integrating synthetic constructs into cellular systems. CRISPR/Cas systems, base editing, and transposon-mediated delivery methods enable targeted insertion of designed sequences into immune cell genomes, often at safe harbor loci that support stable and consistent expression [220]. Microfluidic electroporation and viral-vector platforms have been optimized for parallel processing of primary T or NK cells, enabling libraries of engineered variants to be generated under controlled conditions [221]. Each design instance is annotated with its origin, parameters, and vector architecture, enabling a traceable linkage between computational proposals and their biological realization. This traceability is critical for both reproducibility and regulatory compliance, ensuring transparent lineage from digital design to physical construct.

Emerging cell-free systems provide an intermediate layer of validation between computational design and cellular implementation. DNA templates or mRNA constructs can be expressed in vitro to assay folding, binding, or signaling activity before introduction into living cells [222,223]. These rapid screening layers reduce the cost and biosafety burden associated with testing AI-generated sequences. Integration with laboratory information management systems ensures that metadata, sequence provenance, and performance metrics are seamlessly fed back into the digital design environment [224].

7.3. The Test Phase: High-Dimensional and Multiscale Evaluation

Testing constitutes the sensory layer of the design–build–test–learn system, translating experimental outcomes into quantitative metrics that inform subsequent model refinement. High-throughput display systems—yeast, phage, or mammalian—provide initial binding and expression readouts for receptor libraries [103]. Flow cytometry and surface plasmon resonance quantify affinity and kinetic constants, while single-cell assays capture functional endpoints such as cytokine release, proliferation, or exhaustion markers [225].

Recent advances in multi-omic screening have enhanced the resolution and depth of analytical testing. Single-cell RNA sequencing, proteomic barcoding, and metabolomic profiling characterize thousands of engineered cells simultaneously, revealing how synthetic constructs reshape global cellular states [226]. Spatial transcriptomics and live-cell imaging provide contextual information about cell–cell interactions, trafficking, and synapse formation.

These high-dimensional data streams are analyzed using unsupervised embedding techniques and graph-based clustering methods to extract latent features that represent functional archetypes. Statistical coupling between design parameters and phenotypic readouts allows causal inference about which molecular features drive performance. Importantly, uncertainty quantification metrics inform the selection of candidates for in-depth mechanistic analysis, ensuring that the testing phase not only validates designs but also enhances the informational value of subsequent learning cycles [227]. Incorporating Bayesian calibration and explainable modeling frameworks can further ensure that performance gains are mechanistically interpretable rather than purely correlational.

At scale, the DBTL loop reframes the laboratory itself as a sensory interface for artificial intelligence. The Test phase is not merely a validation checkpoint but the primary data-generation mechanism that determines how rapidly and accurately models can learn. The throughput, quality, and dimensionality of experimental measurements therefore directly constrain the learning rate of the overall generative system. As a consequence, advances in generative immunoengineering are intrinsically coupled with advances in high-content experimental automation, including single-cell multi-omics, live-cell imaging, and parallelized functional assays. In this regime, the principal bottleneck may shift from computational design capacity to empirical characterization, positioning experimental infrastructure as a rate-limiting component of algorithmic progress [228].

7.4. The Learn Phase: Model Updating and Active Reinforcement

The learning phase closes the feedback loop by translating empirical results into updated model parameters. Instead of static retraining, modern systems employ online learning architectures in which models ingest experimental data in near real time [154,229]. Each new data batch adjusts the model’s latent embeddings, probability weights, and uncertainty estimates, progressively aligning computational predictions with biological reality.

Active learning strategies identify experiments that most efficiently reduce model uncertainty. The algorithm selects a subset of candidates predicted to yield the highest information gain, focusing experimental resources on the most informative regions of design space [9]. Reinforcement learning further couples the model to the physical system, whereby successful experimental outcomes generate reward signals that bias subsequent generative sampling toward more productive directions.

In practice, these adaptive feedback mechanisms give rise to a cyber-physical learning system—an integrated framework in which computational and biological components co-evolve. Each iteration not only refines the model’s internal representation but also generates new empirical priors that expand its capacity to generalize [230]. The result is a substantial acceleration of discovery efficiency, with each loop yielding designs of higher predicted performance and lower variance between simulation and experiment. This iterative refinement embodies a data-driven analogue of biological evolution, comprising variation, selection, and retention implemented within an AI-governed experimental ecosystem.

7.5. Automation, Data Infrastructure, and Self-Optimizing Biofoundries

At scale, DBTL becomes inseparable from automation. Modern biofoundries integrate robotics, microfluidics, and advanced data orchestration to enable continuous closed-loop experimentation. AI design servers communicate directly with robotic assembly lines through standardized APIs, initiating synthesis and testing sequences without manual intervention [231,232]. Real-time sensor data, including temperature, reagent usage, cell viability, and expression levels, are streamed to cloud infrastructures, where they synchronize model updates.

Digital twins of the laboratory simulate physical processes in silico, allowing predictive scheduling, error correction, and adaptive re-prioritization of experimental tasks. These twins maintain a live correspondence between virtual and real experiments, permitting instantaneous recalibration when deviations occur [233]. Integration with edge-computing modules enables local decision-making, reducing latency between data acquisition and design refinement.

Data interoperability is central to scaling. Standardized ontologies (e.g., SBOL, AnIML, MIFlowCyt) and metadata schemas ensure that information from diverse instruments and facilities can be aggregated for cross-institutional learning. Cloud-native data lakes equipped with version control and provenance tracking store raw and processed datasets, supporting reproducibility and regulatory auditing [234,235]. Standardization of both data semantics and experiment-level metadata remains a bottleneck, underscoring the importance of community-driven interoperability initiatives.

As these infrastructures mature, self-optimizing biofoundries are emerging as facilities where generative AI orchestrates the entire pipeline from molecular design to functional evaluation. Such systems can autonomously evolve improved receptor variants, optimize circuit architectures, and fine-tune culture parameters to enhance yield or stability [236]. Over time, the accumulated dataset functions as an institutional memory, enabling transfer learning across projects and facilitating the continuous improvement of both algorithms and experimental protocols.

7.6. Integrative and Translational Implications

The large-scale implementation of DBTL frameworks in immunoengineering signifies a structural reorganization of biological knowledge production. Instead of discrete projects defined by static hypotheses, research becomes a dynamic optimization process governed by real-time feedback [237,238]. Generative models no longer operate as isolated analytical tools but as components of an evolving experimental ecosystem.

At the translational level, scalable DBTL systems accelerate the path from computational concept to clinical candidate. By systematically linking receptor sequence, cell phenotype, and manufacturing parameters, these platforms can identify predictive markers of efficacy and safety early in development [239,240]. Closed-loop optimization also supports adaptive manufacturing, where process parameters are adjusted algorithmically to maintain product quality in response to real-time analytics.

Ultimately, the convergence of generative AI, automation, and scalable experimentation transforms immunoengineering into a continuously learning infrastructure. Each iteration expands the collective intelligence encoded in both digital models and biological systems, gradually approaching a regime in which the boundaries between designing, testing, and learning from immunity become increasingly indistinguishable. This architecture represents the operational foundation of programmable immunity, translating theoretical possibility into a self-refining experimental reality. In this architecture, the DBTL framework functions not merely as an engineering workflow but as a new epistemological paradigm for biological design, in which knowledge generation, model evolution, and therapeutic innovation proceed as an inseparable continuum.

8.1. Versioning, Algorithmic Dossiers, and the Identity of Adaptive Cell Therapies

As generative immunoengineering systems mature, translational challenges shift from the approval of individual entities toward the governance of adaptive therapeutic platforms. In this context, versioning emerges as a critical regulatory concept. When a generative model is retrained and produces an updated construct—for example, a “CAR-T version 2.0”—the central question becomes whether this update represents an incremental refinement within a validated design envelope or the creation of a fundamentally new biological entity.

Addressing this distinction requires moving beyond static molecular descriptions toward algorithmic dossiers that document design lineage, training data provenance, conditioning variables, and objective functions across iterative development cycles. Rather than treating each generated construct as an isolated product, the therapeutic identity can be framed at the platform level, with predefined boundaries specifying permissible variation in sequence, signaling architecture, or phenotypic output. Updates that remain within these validated boundaries may be considered iterative improvements, whereas changes that alter the mechanism of action, state-space occupancy, or risk profile would necessitate additional preclinical or clinical evaluation.

This challenge is further amplified by the biological reality that immune cells occupy a high-dimensional state space defined by transcriptional, epigenetic, and metabolic variables, all of which evolve dynamically in response to environmental stimuli [241]. Small algorithmic or construct-level modifications can therefore propagate nonlinearly across cellular states, underscoring the need for version-aware oversight that integrates computational change logs with empirical phenotypic validation. Framing adaptive immune therapies through the lens of versioned platforms, rather than static entities, provides a principled pathway for balancing continuous learning with regulatory rigor.

Despite rapid progress in generative modeling and experimental validation, the single largest barrier preventing AI-designed TCRs from entering clinical trials in 2025 is not algorithmic performance but regulatory-grade validation of safety and specificity. While models can now generate high-affinity, structurally plausible receptors, current pipelines lack standardized, regulator-accepted frameworks for demonstrating the absence of hazardous cross-reactivity at the scale required for first-in-human testing. Predicting rare but catastrophic off-target recognition remains extremely difficult due to incomplete coverage of the human peptidome, limited negative datasets, and imperfect structural generalization [124, 242-243]. As a result, translation is constrained less by design capability than by the need for scalable, trusted preclinical safety evaluation systems that combine large off-target libraries, structure-aware screening, and high-throughput functional assays under regulatory oversight.

At the foundation of this transformation is the capacity of generative models to accelerate discovery and optimization with unprecedented efficiency. Large-scale protein and cellular language models trained on structural, sequence, and binding-affinity data can propose millions of receptor or circuit variants that satisfy pre-defined biophysical and functional constraints. Multi-objective optimization—combining Bayesian inference, reinforcement learning, and evolutionary search—allows competing design criteria such as affinity, folding stability, and manufacturability to be reconciled within a single probabilistic framework [147,216]. When coupled to high-throughput synthesis and functional screening, these algorithms transform receptor design from an empirical search into a statistically guided exploration of sequence space. Early analyses suggest that such workflows can reduce the experimental burden by an order of magnitude, compressing timelines that once spanned years into weeks, although this acceleration remains contingent on access to high-quality multimodal training data and harmonized experimental standards, while preserving, and in some cases improving, success rates in identifying viable therapeutic constructs.

Beyond speed, the generative paradigm introduces the possibility of genuine personalization. Patient-derived molecular data, including tumor transcriptomes, HLA genotypes, immune repertoire sequencing, and single-cell multi-omics, can serve as conditioning variables for model inference [213]. This enables the generation of individualized T-cell receptors or chimeric antigen receptors that are predicted to engage patient-specific neoantigens while minimizing self-reactivity. In principle, these digital blueprints can be synthesized directly into autologous lymphocytes or natural-killer cells within closed, automated manufacturing systems [244]. Crucially, the same framework enables adaptive therapy, in which continuous molecular monitoring through circulating tumor DNA, antigen-escape profiling, or cytokine dynamics is fed back into retraining models to update therapeutic constructs in response to disease evolution. This continuous feedback loop effectively transforms treatment into a dynamic control process, aligning therapeutic pressure with tumor or immune-escape kinetics in near real time. Therapy thus becomes a dynamic equilibrium—a co-adaptive process in which the treatment learns from the patient as much as the patient responds to the treatment [245].

Realizing this adaptive vision requires new regulatory and clinical-trial architecture. Current frameworks presuppose fixed molecular entities, yet generative therapeutics are inherently dynamic. Regulatory bodies have begun developing guidance under the principles of Good Machine Learning Practice, emphasizing transparency, explainability, and post-deployment surveillance. Adaptive or platform trials may replace static designs, enabling algorithmically derived construct revisions within predefined boundaries. Version-controlled documentation of model parameters, training data, and validation outcomes will constitute an “algorithmic dossier,” analogous to the chemistry-manufacturing-controls documentation required for biologics [246,247]. Post-market oversight is expected to include continuous monitoring for model drift and periodic re-certification of retrained algorithms. Together, these mechanisms will form the basis of a new discipline, regulatory bioinformatics, dedicated to the governance of learning systems in medicine. Such governance will likely integrate algorithmic explainability metrics, model-card disclosures, and standardized digital audit trails to ensure accountability throughout the therapeutic life cycle.

Translation from digital design to clinical-grade production further depends on automation and digital infrastructure. AI-integrated biofoundries now link computational design platforms directly to robotic assembly systems, viral vector packaging workflows, and closed-system cell expansion, creating an unbroken digital thread from algorithmic design to physical manufacture. Each construct carries a persistent identifier that links its computational origin to its production batch, ensuring traceability throughout the product life cycle [248]. Digital-twin bioreactors simulate nutrient gradients, cytokine signaling, and metabolic flux in real time, adjusting culture conditions through reinforcement-learning controllers to preserve cell viability and phenotypic stability. Multi-omic sensors monitoring transcriptomic, impedance, and metabolic signatures provide continuous data streams to these control layers, enabling predictive correction of deviations before product quality is compromised. Such cyber-physical feedback transforms Good Manufacturing Practice environments from static production lines into adaptive learning systems that improve with every run [249,250]. Collectively, these infrastructures reconceptualize Good Manufacturing Practice (GMP) as a dynamic rather than static framework, in which quality is ensured through continuous sensing, prediction, and correction, rather than reliance on retrospective testing.

Although oncology remains the initial testing ground, the principles of generative immunoengineering are applicable across diverse therapeutic landscapes. In solid tumors, generative models are being used to design multispecific and logic-gated CAR architectures that enhance selectivity and persistence while mitigating off-target toxicity. In autoimmunity, the same computational logic can be applied to the design of regulatory T-cell or dendritic-cell circuits that restore immune tolerance without inducing systemic immunosuppression. Regenerative medicine may benefit from engineered macrophage or tolerogenic antigen-presenting cell designs optimized for cytokine balance and metabolic resilience, thereby promoting tissue repair and graft acceptance (Supplementary Table S3) [67, 117, 251-259]. Similar approaches extend to infectious-disease preparedness, where rapid, model-driven updates to antigen or receptor design could allow immune interventions to evolve as quickly as the pathogens they target.

Ensuring the safety and interpretability of algorithmically derived constructs remains paramount. Multi-layered validation pipelines combine in silico prediction, explainable-AI analysis, and empirical verification. Generative outputs are screened for immunogenic motifs, structural instability, and potential off-target binding before synthesis. These in silico safeguards are complemented by human-in-the-loop review protocols, ensuring that overreliance on automated predictions is avoided in high-risk therapeutic contexts. Attention-based visualization and feature-attribution mapping identify sequence regions most influential in the model’s predictions, while uncertainty quantification provides calibrated confidence estimates. Empirical assays ranging from multiplex peptide arrays to single-cell cytotoxicity screens serve as orthogonal tests of computational accuracy [260,261]. To formalize accountability, proposed standards for Algorithmic Documentation Files will record the architecture, data provenance, and performance metrics of each deployed model, enabling reproducibility and auditability across regulatory jurisdictions [262].

Economic and infrastructural considerations are equally transformative. The high up-front computational investment in data curation and model training is counterbalanced by substantial downstream savings from reduced screening, accelerated iteration, and automated manufacturing. Distributed biofoundries connected through secure cloud infrastructures could enable regional or hospital-based production of autologous therapies, thereby reducing logistical complexity and dependence on cold-chain systems. Achieving this vision will require harmonized digital quality-management systems and interoperable GMP documentation across sites. Ensuring equitable access to these infrastructures, particularly in low- and middle-income regions, will be critical to preventing a widening translational divide in personalized immunotherapy. Health-economic evaluation frameworks must evolve to recognize the amortized value of continuously improving algorithms and the outcomes they enable, transitioning from static cost-effectiveness assessments toward performance-linked reimbursement models [263].

The ethical, legal, and social implications of generative immunoengineering must evolve alongside its technical capabilities. The use of clinical and genomic data for model training requires explicit consent frameworks that define the use of secondary and longitudinal data. Questions of intellectual property, including whether ownership resides in datasets, model architectures, or generated sequences, require global policy coordination. Dual-use risks are real; systems capable of designing potent therapeutic receptors could, in principle, be misused to generate immune-evasive or pathogenic molecules. Safeguarding measures analogous to existing biosecurity treaties will be essential, along with equitable access to computational infrastructure to prevent the concentration of capability within a small number of technologically privileged centers. Open repositories, distributed compute alliances, and internationally governed consortia can help ensure that the benefits of programmable immunity are shared globally rather than confined to specific regions or sectors [264,265].

Taken together, these translational trajectories delineate the emergence of a new therapeutic paradigm. In the near term, AI-optimized CAR and TCR constructs with integrated safety and quality-monitoring frameworks are poised to enter early-phase trials. Over the next decade, standardized digital biofoundries and adaptive regulatory pipelines are likely to support the extension of this technology to autoimmune, transplant, and regenerative contexts [117]. Beyond this horizon lies the prospect of a continuously learning therapeutic ecosystem in which each patient outcome refines the generative models that inform subsequent design. In this envisioned future, therapeutic innovation and biological understanding become increasingly inseparable, and the immune system is reconceptualized as a programmable interface between computation and living systems. This is the defining hallmark of AI-enabled generative design of immune cells and receptors for programmable immunity [266]. This synthesis of adaptive intelligence and living matter marks not only a technological milestone but a conceptual redefinition of medicine itself, one in which therapy, learning, and evolution converge within a single generative continuum.

9.1. Embedded Ethics in Generative Immunoengineering

Ethical governance in generative immunoengineering cannot be treated as an external review layer applied post hoc to technical development. Instead, ethics must be embedded directly within the DBTL loop, co-evolving with algorithms, data, and engineered cells. In programmable immunity, governance itself must be programmable, adaptive, and technically instantiated within the same workflows that generate biological function.

At the design stage, ethical constraints can be formalized as optimization objectives rather than qualitative guidelines. Fairness and bias metrics may be incorporated directly into model loss functions or reinforcement learning reward signals, ensuring that generated receptors or cell programs do not systematically favor specific genetic backgrounds, tissue contexts, or demographic groups. Similarly, algorithmic explainability can be treated as a required design output, with interpretable representations and causal attributions generated alongside candidate constructs rather than as post hoc audits.

At the data and infrastructure level, embedded ethics motivates the adoption of privacy-preserving architectures as default components of generative modeling pipelines. Federated learning, secure multiparty computation, and differential privacy enable models to learn from distributed clinical and genomic datasets without centralizing sensitive patient information. Integrating these approaches into biofoundry-linked DBTL systems ensures that scale and learning efficiency are not achieved at the expense of privacy, consent, or data sovereignty.

During testing and learning, ethical governance continues through continuous monitoring of safety, uncertainty, and downstream risk. Experimental feedback not only refines performance predictions but also updates ethical risk assessments, enabling models to adaptively constrain exploration of designs associated with elevated immunogenicity, off-target activity, or misuse potential. In this framework, ethics is not treated as a static compliance checkpoint but as a dynamic control layer that constrains and guides generative exploration throughout the lifecycle of adaptive immune therapies.

The following paragraphs examine how this embedded ethical logic manifests across data stewardship, interpretability, regulatory oversight, and societal impact.

At the ethical level, the most immediate concern involves the use of patient-derived data for model training and algorithmic conditioning. The effectiveness of generative immunoengineering depends on access to large, high-quality datasets encompassing genomic, proteomic, and clinical information. Yet the aggregation of such data, often derived from identifiable biological samples, raises questions regarding consent, ownership, and longitudinal use. Current consent models, designed for discrete studies, are poorly suited to the continuous learning paradigm of AI-driven research. Dynamic or “evergreen” consent frameworks, allowing participants to renew, modify, or revoke data permissions as models evolve, may become essential to align data use with individual autonomy [269-271]. In clinical settings, such adaptive consent mechanisms must be coupled with continuous feedback loops between patients and therapeutic models, ensuring that participants retain agency as their biological and computational profiles co-evolve. Likewise, new institutional mechanisms will be needed to recognize participants not merely as data donors but as contributors to the generative process, with potential claims to benefit-sharing or acknowledgment. Incorporating underrepresented populations into training datasets is also essential to mitigate demographic bias and to ensure the global generalizability of AI-driven immune design.

Transparency and explainability constitute a second ethical axis. The interpretability of generative outputs is crucial for both scientific trust and clinical safety. Recent advances in attention mapping, saliency analysis, and uncertainty quantification have enhanced interpretability of how models generate biological designs; however, a persistent epistemic gap remains between statistical pattern recognition and causal biological reasoning. Regulators, clinicians, and researchers must therefore treat algorithmic explainability not as an optional feature but as a moral imperative. Documentation of model lineage, training data provenance, and version history should be regarded as an integral component of ethical disclosure, comparable in importance to reporting methods in experimental science [272,273]. Bridging this interpretive gap will require hybrid frameworks that combine mechanistic modeling with data-driven generation so that algorithmic creativity remains biologically intelligible. In the absence of such transparency, the reproducibility crisis observed in other disciplines may extend to synthetic immunology, thereby undermining confidence in AI-mediated design.

Regulatory institutions now face the challenge of governing entities that are not static products, but dynamic, continuously evolving systems. Conventional approval pathways, designed for fixed molecular entities, cannot easily accommodate therapeutic platforms that learn from new data and autonomously propose novel constructs [274]. Emerging frameworks under the rubric of Good Machine Learning Practice (GMLP) attempt to address this tension by introducing algorithmic change-control mechanisms, documentation standards, and real-time performance monitoring (Figure 4). In the context of generative immunoengineering, such regulation will likely require integration of algorithmic dossiers into the chemistry-manufacturing-controls infrastructure of GMP [275]. Each generative model may be regarded as a “living protocol” subject to continuous validation and regulatory auditing. This convergence of computational oversight and biomanufacturing control represents a defining shift in the governance of biomedical AI and will require cross-trained professionals fluent in both algorithmic governance and Good Manufacturing Practice (GMP) compliance.

A further dimension of ethical responsibility arises from dual-use potential and biosecurity. The same generative architectures that optimize immune recognition could, in principle, be repurposed to design immune-evasive pathogens, synthetic toxins, or receptor-binding antagonists. As algorithmic tools proliferate across open scientific ecosystems, the distinction between beneficial and potentially hazardous applications becomes increasingly permeable. Consequently, international biosecurity regimes—traditionally centered on material agents and physical laboratory environments—must expand to incorporate informational biosecurity, encompassing the governance of digital models, codebases, and data pipelines capable of generating biologically relevant functions. Building multi-layered safeguards that combine technical containment, federated architectures, and ethical licensing will be central to future risk management. Developing secure access frameworks such as controlled model release, tiered licensing, and federated training will be essential to balance open scientific exchange with risk mitigation [268,276]. Ethical oversight committees within research institutions should integrate expertise in AI safety and cybersecurity alongside traditional biosafety expertise.

The societal implications of generative immunoengineering extend beyond bioethics into the political economy of biomedical innovation. Given that generative design relies on substantial computational infrastructure and frequently proprietary datasets, there is a concomitant risk that both technological capability and, by extension, access to therapeutic innovation may become increasingly concentrated within a small number of institutions and nations. Without deliberate intervention, the “AI divide” in healthcare could mirror and amplify existing inequities in access to genomic medicine. Counteracting this trend will require international coordination of data-sharing standards, open access repositories for pre-trained biological models, and collaborative licensing arrangements that enable low-resource regions to participate in the development and deployment of AI-driven therapeutics [277,278]. Equitable access is not only a matter of distributive justice but also of scientific robustness. Diversity in training data improves model generalizability and reduces bias, thereby enhancing the safety and effectiveness of therapies across global populations. Moreover, algorithmic asymmetry in data ownership and computational access risks consolidating economic power among a few institutions, creating new forms of biomedical dependency that demand policy-level correction.

The epistemological implications are equally profound. Generative immunoengineering reconfigures the relationship between hypothesis and experimentation, transforming scientific discovery into an iterative dialogue between algorithmic inference and empirical validation [279,280]. This shift blurs the historical boundary between knowledge generation and technological fabrication, forcing a reconsideration of what counts as “understanding” in biology. If a model can design a receptor that functions optimally without the designer fully understanding the underlying causal grammar, the locus of scientific agency shifts from the individual human investigator to a hybrid human–machine system. In this configuration, agency becomes distributed as a co-production of human intention and algorithmic inference, raising new questions about authorship, accountability, and epistemic responsibility. Such transformations invite reflection on the nature of explanation, accountability, and authorship in the age of algorithmic biology. The challenge for future scientific culture will be to ensure that interpretability and conceptual insight evolve alongside performance and automation [279].

Finally, integrating generative immunoengineering into clinical and societal systems will require new governance frameworks that are anticipatory rather than reactive in nature. Ethical frameworks should be embedded from the outset of model development, not retrofitted in response to controversy. Cross-disciplinary oversight bringing together immunologists, data scientists, ethicists, clinicians, and patient representatives should guide decisions regarding data use, design objectives, and therapeutic deployment. International consortia may serve as coordinating bodies to establish shared principles for algorithmic transparency, data equity, and biosafety. As generative biology becomes increasingly autonomous, the human responsibility for defining its boundaries and purposes becomes more, not less, essential. The future of programmable immunity will therefore depend not only on the sophistication of its algorithms, but also on the moral architecture of the institutions that steward them [268]. Only through ethically adaptive governance can programmable immunity mature into a discipline that preserves both biological integrity and public trust in the era of generative medicine.